Update on Biomarkers for the Detection of Lung Cancer

Overview

Journal Lung Cancer (Auckl)

Publisher Dove Medical Press

Date 2017 Feb 18

PMID 28210122

Citations 19

Authors

Eloisa Jantus-Lewintre

Marta Uso

Elena Sanmartin

Carlos Camps

Affiliations

Soon will be listed here.

Abstract

Patients at risk for lung cancer may have subclinical disease for years before presentation. The diagnosis of this disease is primarily based on symptoms, and detection often occurs after curative intervention is no longer possible. At present, no lung cancer early-detection biomarker is clinically available. This study reviews the most recent advances in early detection and molecular diagnostic biomarkers for the detection of lung cancer. This review includes an overview of the various biological specimens and matrices in which these biomarkers could be analyzed, as well as the diverse strategies and approaches for identifying new biomarkers that are currently being explored. Several novel and attractive biomarker candidates for the early detection of lung cancer exist. A remarkable shift is taking place from research based on single markers to analyzing signatures that are more complex in order to take advantage of new high-throughput technologies. However, it is still necessary to validate the most promising markers and the standardization of procedures that will lead to specific clinical applications.

Citing Articles

Combining Metabolomics and Machine Learning to Identify Diagnostic and Prognostic Biomarkers in Patients with Non-Small Cell Lung Cancer Pre- and Post-Radiation Therapy.

Murcia-Mejia M, Canela-Capdevila M, Garcia-Pablo R, Jimenez-Franco A, Jimenez-Aguilar J, Badia J Biomolecules. 2024; 14(8).

PMID: 39199286 PMC: 11353221. DOI: 10.3390/biom14080898.

Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinoma .

Pan J, Zhuang W, Xia Y, Huang Z, Zheng Y, Wang X PeerJ. 2024; 12:e17141.

PMID: 38529301 PMC: 10962332. DOI: 10.7717/peerj.17141.

Proline Dehydrogenase (PRODH) Is Expressed in Lung Adenocarcinoma and Modulates Cell Survival and 3D Growth by Inducing Cellular Senescence.

Grossi S, Berno E, Chiofalo P, Chiaravalli A, Cinquetti R, Bruno A Int J Mol Sci. 2024; 25(2).

PMID: 38255788 PMC: 10815008. DOI: 10.3390/ijms25020714.

Evaluation of Expression Levels of NFATc2 and PPARG Genes Two Effector Elements of WNT Pathway in Non-Small Cell Lung Carcinoma.

Motamediyan K, Zafari V, Bornehdeli S, Caner A, Asadi M, Hashemzadeh S Adv Biomed Res. 2023; 12:184.

PMID: 37694246 PMC: 10492599. DOI: 10.4103/abr.abr_185_22.

Fucosylated exosomal miRNAs as promising biomarkers for the diagnosis of early lung adenocarcinoma.

Chen X, Yu L, Hao K, Yin X, Tu M, Cai L Front Oncol. 2022; 12:935184.

PMID: 36033494 PMC: 9414872. DOI: 10.3389/fonc.2022.935184.

References

Febbo P, Ladanyi M, Aldape K, De Marzo A, Hammond M, Hayes D . NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011; 9 Suppl 5:S1-32. DOI: 10.6004/jnccn.2011.0137. View

Halling K, Rickman O, Kipp B, Harwood A, Doerr C, Jett J . A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest. 2006; 130(3):694-701. DOI: 10.1378/chest.130.3.694. View

Bajtarevic A, Ager C, Pienz M, Klieber M, Schwarz K, Ligor M . Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer. 2009; 9:348. PMC: 2761408. DOI: 10.1186/1471-2407-9-348. View

Martin K, Fournier M, Reddy G, Pardee A . A need for basic research on fluid-based early detection biomarkers. Cancer Res. 2010; 70(13):5203-6. DOI: 10.1158/0008-5472.CAN-10-0987. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Schneider K, Dietrich D, Fleischhacker M, Leschber G, Merk J, Schaper F . Correlation of SHOX2 gene amplification and DNA methylation in lung cancer tumors. BMC Cancer. 2011; 11:102. PMC: 3070682. DOI: 10.1186/1471-2407-11-102. View

Schramm M, Wrobel C, Born I, Kazimirek M, Pomjanski N, William M . Equivocal cytology in lung cancer diagnosis: improvement of diagnostic accuracy using adjuvant multicolor FISH, DNA-image cytometry, and quantitative promoter hypermethylation analysis. Cancer Cytopathol. 2011; 119(3):177-92. DOI: 10.1002/cncy.20142. View

Andriani F, Conte D, Mastrangelo T, Leon M, Ratcliffe C, Roz L . Detecting lung cancer in plasma with the use of multiple genetic markers. Int J Cancer. 2003; 108(1):91-6. DOI: 10.1002/ijc.11510. View

Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F . MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011; 108(9):3713-8. PMC: 3048155. DOI: 10.1073/pnas.1100048108. View

10.

ODonnell K, Wentzel E, Zeller K, Dang C, Mendell J . c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435(7043):839-43. DOI: 10.1038/nature03677. View

11.

Sung H, Cho J . Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep. 2008; 41(9):615-25. DOI: 10.5483/bmbrep.2008.41.9.615. View

12.

Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K . Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res. 2005; 11(3):1219-25. View

13.

McWilliams A, Lam B, Sutedja T . Early proximal lung cancer diagnosis and treatment. Eur Respir J. 2009; 33(3):656-65. DOI: 10.1183/09031936.00124608. View

14.

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

15.

Tyan Y, Wu H, Lai W, Su W, Liao P . Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry. J Proteome Res. 2005; 4(4):1274-86. DOI: 10.1021/pr049746c. View

16.

Ostrow K, Hoque M, Loyo M, Brait M, Greenberg A, Siegfried J . Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res. 2010; 16(13):3463-72. PMC: 2899894. DOI: 10.1158/1078-0432.CCR-09-3304. View

17.

Fleischhacker M, Schmidt B . Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2006; 1775(1):181-232. DOI: 10.1016/j.bbcan.2006.10.001. View

18.

Sirera R, Bremnes R, Cabrera A, Jantus-Lewintre E, Sanmartin E, Blasco A . Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011; 6(2):286-90. DOI: 10.1097/JTO.0b013e31820189a5. View

19.

Hanash S, Baik C, Kallioniemi O . Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011; 8(3):142-50. DOI: 10.1038/nrclinonc.2010.220. View

20.

Carpagnano G, Foschino-Barbaro M, Spanevello A, Resta O, Carpagnano F, Mule G . 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer. Am J Respir Crit Care Med. 2007; 177(3):337-41. DOI: 10.1164/rccm.200707-1136OC. View